Glucose Metabolism in CFRD: Exploring the Role of CFTR Modulators in Metabolic Dysfunction
The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR modulator (ETI) therapy (CFRDF508del+ETI). CFRD with a mutation that is not eligible for modulator therapy (CFRD-ETI) will be the control group.
⁃ Individuals who have at least one copy of the F508 deletion and are on ETI medications and individuals who have a different mutation and are not eligible for ETI medications
⁃ Age 21-75 years at time of consent
⁃ BMI 19-50 kg/m2 (In Asians BMI is \
• 2 points lower for comparison so it is 17-48 kg/m2)
⁃ Creatinine ≤ 1.4 mg/dl in women and ≤ 1.5 mg/dl in men
⁃ HbA1c ≤ 11% lifestyle treatment or mono/combination therapy with oral hypoglycemic agents (e.g. metformin or sulphonylurea or SGLT2i) and/or insulin.
⁃ Willing to be at a stable weight for duration of the study.
⁃ An understanding of and willingness to follow the protocol and sign the informed consent